Kane Biotech Announces Closing of Private Placement Offering
WINNIPEG, Manitoba (December 14, 2012) – Kane Biotech Inc. (TSX-V:KNE) (the “Corporation”) today announced closing of the Corporation’s previously announced non-brokered private placement offering (the “Offering”) units (“Units”) at a price of $0.08 per Unit. Each Unit is comprised of…
Kane Biotech Appoints Dr. Arvind K. Joshi, M.D. to the Board of Directors
WINNIPEG, Manitoba (November 28, 2012) – Kane Biotech Inc. (TSX-V: KNE), a biotechnology company developing and commercializing products that prevent and remove microbial biofilms, announces today the appointment of Dr. Arvind K. Joshi, M.D. F.R.C.S.(C),F.A.C.O.G.,M.B.A.,C.H.E.to its Board of Directors.
Dr.…
Kane Biotech Receives Health Canada Approval for KBI Disinfectant Label Expansion
WINNIPEG, Manitoba (November 27, 2012) – Kane Biotech Inc. (TSX-V: KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received approval from the Therapeutic Products…
Kane Biotech Prepares to Launch StrixNB™ Pet Oral Care Product
WINNIPEG, Manitoba (November 20, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce it has received Notification Number“NN.W33A” from the Low Risk…
Kane Biotech Successfully Completes Veterinary Clinic Testing of StrixNB™
WINNIPEG, Manitoba (November 15, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces it has successfully completed the veterinary clinic testing of its pet oral…
Kane Biotech Announces Private Placement Offering
WINNIPEG, Manitoba (November 14, 2012) – Kane Biotech Inc. (TSX-V:KNE)(the “Corporation”) today announced the intention of the Corporation to undertake a non-brokered private placement offering (the “Offering”) of up to 18,750,000 units (“Units”) at a price of $0.08 per Unit…
Kane Biotech Issued New Patent in Australia for Aledex®
WINNIPEG, Manitoba (November 06, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.2006265707) entitled “Antimicrobial compositions for…
Kane Biotech and Avmor Sign Licensing Agreement for KBI Disinfectant in Canada
WINNIPEG, Manitoba (October 25, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has signed a non-exclusive licensing agreement…
Kane Biotech Issued New Patent in Japan for DispersinB®
WINNIPEG, MB. (October 16, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce the issuance of Patent (No.5073169) entitled “Compositions and Methods…
Kane Biotech Completes Pilot Manufacturing Phase of StrixNB™ Oral Care Product
WINNIPEG, MB. (October 10, 2012) – Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms is pleased to announce that the Company has successfully developed the manufacturing process…